Effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia: a meta-analysis of randomized controlled trials

非布索坦 高尿酸血症 别嘌呤醇 医学 随机对照试验 荟萃分析 痛风 尿酸 内科学 科克伦图书馆 药理学
作者
Hong Xie,Nan Hu,Ting Pan,Jun-Cai Wu,Miao Yu,Deng-Chao Wang
出处
期刊:BMC Clinical Pharmacology [BioMed Central]
卷期号:24 (1)
标识
DOI:10.1186/s40360-023-00723-5
摘要

Abstract Background The prevalence of hyperuricemia has increased steadily with the continuous improvement of living standards. Some studies have reported the clinical effectiveness and safety of different doses of febuxostat in comparison with allopurinol in hyperuricemia treatment, but the sample sizes of the studies have been small, and the results have been inconsistent. We designed this meta-analysis to evaluate the effectiveness and safety of different doses of febuxostat compared with allopurinol in the treatment of hyperuricemia. Methods The Cochrane Library, Embase, PubMed, Web of Science and ClinicalTrials.gov databases were searched to identify randomized controlled trials (RCTs) comparing the use of febuxostat and allopurinol for the treatment of hyperuricemia. The effectiveness and safety of different doses of febuxostat and allopurinol in treating hyperuricemia were assessed using meta-analysis. Results A total of 11 randomized controlled trials were included in the meta-analysis. The results of the meta-analysis showed that the percentage of patients achieving serum uric acid levels of 6.0 mg/dL or less was higher among patients taking febuxostat (80 mg/d) than among patients taking allopurinol (200–300 mg/d) [RR = 1.79, 95% CI (1.55, 2.08), P < 0.00001]. However, there was no statistically significant difference in the percentage of patients achieving serum uric acid levels of 6.0 mg/dL or less between febuxostat (40 mg/d) and allopurinol (200–300 mg/d) [RR = 1.10, 95% CI (0.93, 1.31), P = 0.25]. There was also no statistically significant difference in the incidence of gout between the febuxostat (40 mg/d) and allopurinol (200–300 mg/d) [RR = 0.97, 95% CI (0.64, 1.49), P = 0.91] or between the febuxostat (80 mg/d) and allopurinol (200–300 mg/d) [RR = 1.13, 95% CI (0.81, 1.58), P = 0.48].No significant difference in the incidence of major adverse reactions as observed between the febuxostat (40 mg/d) and allopurinol (200–300 mg/d) [RR = 1.16; 95% CI (0.43, 3.16), P = 0.77] or between the febuxostat (80 mg/d) and allopurinol (200–300 mg/d) [RR = 1.06; 95% CI (0.79, 1.42), P = 0.70]. The incidence of adverse cardiovascular events did not differ significantly between the febuxostat (40 mg/d) and allopurinol (200–300 mg/d) [RR = 1.30; 95% CI (0.57, 2.95), P = 0.53] or between the febuxostat (80 mg/d) and allopurinol (200–300 mg/d) [RR = 1.79; 95% CI (0.74, 4.32), P = 0.20]. Conclusions Febuxostat (80 mg/d) was associated with a higher percentage of patients achieving serum uric acid levels of 6.0 mg/dL or less than allopurinol (200–300 mg/d), however, febuxostat (80 mg/d) did not exhibit better efficacy in reducing the incidence of gout. More attention should be devoted to the adverse reactions caused by an increase in febuxostat doses.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
FashionBoy的应助被熙可檬采纳,获得20
1秒前
莉莉丽发布了新的文献求助10
1秒前
廾匸完成签到 ,获得积分10
1秒前
1秒前
嘟噜发布了新的文献求助10
2秒前
隐形曼青的应助被落后访波采纳,获得10
2秒前
2秒前
Z_jx完成签到,获得积分10
2秒前
2秒前
3秒前
淡淡网络发布了新的文献求助10
4秒前
4秒前
4秒前
4秒前
5秒前
allan完成签到,获得积分20
5秒前
5秒前
打打的应助被WangJ1018采纳,获得10
5秒前
6秒前
Tutor完成签到,获得积分10
6秒前
7秒前
7秒前
沉静向梦发布了新的文献求助50
7秒前
8秒前
8秒前
wanci的应助被qianyu采纳,获得10
8秒前
8秒前
烦不烦发布了新的文献求助10
9秒前
快乐发带发布了新的文献求助10
9秒前
www发布了新的文献求助10
10秒前
10秒前
10秒前
研友_VZG7GZ的应助被h11采纳,获得10
10秒前
研友_VZG7GZ的应助被内向的问夏采纳,获得30
11秒前
001发布了新的文献求助10
11秒前
yang完成签到 ,获得积分10
12秒前
王大拿新完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8164445
求助须知:如何正确求助?哪些是违规求助? 9558283
关于积分的说明 21744871
捐赠科研通 7754979
什么是DOI,文献DOI怎么找? 3428582
关于科研通互助平台的介绍 2553119
邀请新用户注册赠送积分活动 2473142